Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Hepatitis C 1

Interventions

Cisplatin 352Oxaliplatin 262Capecitabine 258Radiotherapy 240Gemcitabine 223Docetaxel 223Carboplatin 223Cyclophosphamide 219Drug Therapy 218Paclitaxel 205apatinib 201Bevacizumab 195camrelizumab 190Fluorouracil 187sintilimab 133Blood Specimen Collection 125Irinotecan 124Dexamethasone 123Etoposide 119Radiosurgery 118toripalimab 117Surgical Procedures, Operative 115pembrolizumab 110Pemetrexed 108anlotinib 105S 1 (combination) 105Surveys and Questionnaires 101Leucovorin 101Nivolumab 98tislelizumab 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × OTHER × ledipasvir, sofosbuvir drug combination × Clear all
NCT03261349 2017-08-25

Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma

National Taiwan University Hospital

Phase 2 Unknown
21 enrolled
Lymphoid

Hepatitis C, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡